We work alongside hospitals to deliver personalized medicine — selecting the best existing drug for each patient, or creating a new one from scratch when nothing else works. What used to take 10–15 years, we do in hours.
Current personalized medicine is built on statistics, not biology. It forgets the molecular rules that govern disease. And when every approved treatment has failed, there is simply nothing left to try.
Today’s drug selection is based on population averages — not on what is happening inside your cells. Real biology is ignored, and patients pay the price.
When all approved treatments have failed a patient, the pipeline ends. There is no extra drug. No final option. No last resort.
Creating a new therapy takes over a decade and costs up to $2 billion. By the time it reaches the patient who needed it, it is already too late.
From a single biopsy, our AI — grounded in real biological rules, not statistics — understands the disease at a molecular level. Then our technology finds or creates the solution.
From a biopsy sample, our AI builds a molecular map of the patient’s disease. No statistics. No black boxes. Pure biology. We then prioritize from all approved drugs what will work best for that specific patient.
When no approved drug works, we create one. We’ve found a way to fit an entire traditional laboratory inside a single living cell. All molecular and toxicology assays now happen in microns — preclinical data and GMP certifications from a device on your table.
When there is nothing else to do, there will still be something else to do. There will be Ajax.
This is what it looks like when biology, AI, and a cell-sized laboratory work together for one patient.
A biopsy sample arrives at our platform. Our AI — grounded in biological rules, not statistics — maps the disease at a molecular level. We understand what’s broken, why, and what can fix it.
→ Hours, not monthsWe prioritize from all approved drugs what will work best. If nothing on the list works, we design new therapeutic candidates. Not hypotheticals — real, testable molecules.
→ From approved drugs to novel solutionsOur Lab On A Cell runs all preclinical assays and toxicology tests in parallel — thousands of candidates in microns of space. One week after admission, the patient begins a personalized clinical trial.
→ 1 week to clinical trial// Patient digital twin: disease pathway simulation
function buildPatientTwin(patientId) {
var genomics = getPatientGenome(patientId);
var proteomics = getProteomics(patientId);
var twin = createDigitalTwin(genomics, proteomics);
return twin.simulateDisease();
}
// Personalized drug screening
function screenTherapies(twin) {
var candidates = generateCandidates(twin.targets);
var results = simulateEfficacy(candidates, twin);
return results.rankByResponse();
}
// Drug-gene interaction prediction
function predictInteractions(drug, patient) {
var pathways = mapDrugTargets(drug);
var risk = assessAdverseEffects(pathways, patient);
if (risk.score < 0.05) {
return approveForTrial(drug);
}
}
// Cellular teleprogramming: on-demand manufacturing
function manufactureTherapy(approvedDrug) {
var cells = programCells(approvedDrug.sequence);
return cells.produceAtBedside();
}
The ecosystem that backs AjaxDNA
Lanzadera
IDEAS UPV
AgrotecUV
Bioval
Food for Life
UPV
ENISA
IBV
VLC Innovation Capital
Recognition from the ecosystem and leading acceleration programs backing AjaxDNA.
Our growing footprint in global media and biotech ecosystems.
Talk to us about how AjaxDNA can help your hospital deliver personalized medicine — from drug selection to personalized clinical trials — in days, not decades.
We evaluate your patient’s case and show you what our platform can do for them.
See how a biopsy becomes a molecular disease map, a drug selection, and a treatment plan.
We design a deployment plan that fits your clinical infrastructure and regulatory requirements.